卷 8, 编号 4 (2018)
- 年: 2018
- 文章: 295
- URL: https://journals.rcsi.science/2220-7619/issue/view/6206
- DOI: https://doi.org/10.15789/2220-7619-2018-4
完整期次
MOLECULAR BASES OF EPIDEMIOLOGY, DIAGNOSTICS, PREVENTION AND TREATMENT OF INFECTIOUS DISEASES
FOREWORD
405-406
JUBILEE 2018: 110th ANNIVERSARY OF THE FOUNDATION OF THE ST. PETERSBURG PASTEUR RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY AND THE 95th ANNIVERSARY OF THE NAMING OF THE INSTITUTE AFTER PASTEUR
摘要
Abstract. The article presents not previously published archive data and copies of documents about Lieberman Yakov Yulievich, the first director of the Petrograd Bacteriological Institute named after Pasteur (now called Saint Petersburg Pasteur Institute). Based on the personal testimony of Ya.Yu. Lieberman, Pyotr Petrovich Maslakovets and Georgii Dmitrievich Belonovsky (the founders and leaders of the Institute) preserved in the archive funds of the Directorate of the Federal Security Service (FSB) of Russian Federation for St. Petersburg and the Leningrad Region, and taking into account the Act of the Commission for the Institute Inspection from December 1930, provided in the article, the authors consistently trace the path of transformations that the Institute has undergone since its foundation. These data are illustrated by copies of publication advertisements contained in the annual city reference book "All Petersburg" for years 1910, 1911, 1912, 1914, 1923, 1924, and 1925 (from the funds of the National Library of Russia). The article also contains copies of official documents dated 1913 and 1914 and stored in the funds of the Central State Historical Archive of St. Petersburg. All documents provided establish the fact that the date of creation of the Institute is 1908.
408-417
DISCIPLES OF PASTEUR FROM RUSSIA
摘要
Abstract. Outstanding scientist, microbiologist, chemist Louis Pasteur left a great legacy to future generations: many discoveries in the relevant fields of science, a large number of disciples, followers and the Paris Institute, bearing his name. Among Pasteur's disciples were more than a hundred Russian scientists, whose fate was different. Some of them returned Home and were able to make a significant contribution to the development of microbiology and immunology in Russia. Not all the names of Pasteur's disciples are known to a wide range of microbiologists. Therefore, the article presents brief materials about some more or less well known scientists-followers of Louis Pasteur. L.S. Tsenkovsky may be considered the founder of microbiology in Russia, who in 1882 published the book "Microorganisms", and later was able to independently create a vaccine against anthrax. Numerous trips to the Pasteur Institute in Paris had a positive value — Lev Semenovich was able to assess how to be equipped laboratories that deal with serious problems in the field of microbiology. Students of Pasteur L.L. Heydenreich, A.D. Pavlovsky, M.F. Popov, A.I. Sudakov, A.A. Raevsky was able not only to develop scientific areas in microbiology, but also to transfer their knowledge to students of medical and veterinary faculties of universities in various cities of Russia, students of the St. Petersburg Military medical Academy and military doctors. I.I. Mechnikov and N.F. Gamalea were great friends and colleagues of Pasteur for many years. Together with Pasteur, they made a great contribution to the prosperity of the Paris Institute and the maintenance of the glory of its founder. The role of these scientists in the world heritage in the field of immunology and microbiology is difficult to overestimate. Associate I.I. Mechnikova was also D.K. Zabolotny, who managed to organize the departments of microbiology and epidemiology in several higher educational institutions of Russia and Ukraine. And, of course, the unsurpassed contribution to the organization of the Pasteur Institute in Russia on the model of the Paris Institute belongs to G.D. Belonovsky. Thanks to his efforts, the Sero-diagnostic laboratory gradually developed into the St. Petersburg Pasteur Institute. Many disciples of Pasteur laid the foundation of a number of scientific areas in Russia: microbiology, immunology, toxicology, hygiene. Thanks to the efforts of enthusiasts among the followers of Louis Pasteur managed to establish in Russia (St. Petersburg) Institute, similar to Paris, also named after him. Each of the disciples of Pasteur thanks to selfless work was able to prove his high rank and make a significant contribution to the development of science for the health of the population of the Homeland.
418-424
PYRAZINAMIDE/PYRAZINOIC ACID RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS: RECENT FINDINGS AND IMPLICATIONS FOR IMPROVING THE TREATMENT OF TUBERCULOSIS
摘要
Abstract. Pyrazinamide (PZA) is unique in that it is a component of the first line therapy for drug sensitive tuberculosis and in most current and experimental treatments also for multi drug resistant tuberculosis. Furthermore, PZA has been shown to help to ensure lasting cure and prevent relapse in shorter multi drug regimens. PZA is a prodrug. Mycobacterial tuberculosis (MTB) PncA enzyme activates the anti-mycobacterial prodrug PZA by transforming it into pyrazinoic acid (POA). The majority of clinical PZA resistant isolates contain mutations within the pncA gene and therefore remain sensitive to POA as they no longer activate PZA. Resistance to the active compound POA requires an alternative resistance mechanism and in vitro selected spontaneous MTB POA resistant mutants typically acquire a range of mutations in panD or mutations in one of a series of genes most of which are associated with the regulation of the bacterial stringent response. Clinically isolated PZA resistant MTB strains resistant to PZA and POA with mutations in any of these genes are unusual. Thus, it is likely the stringent response is critical for MTB in vivo and a damaged stringent response results in at least a reduction in fitness. Various lead compounds that disrupt the MTB stringent response have been identified that might form the basis for drugs with activity against latent mycobacteria with the potential to shorten tuberculosis treatment. Here we discuss the role of latency in the lifecycle of MTB and possible links to the activity PZA with a focus on potential new targets and drugs.
425-434
BIOFILM FORMATION INDUCED BY CLINICAL ISOLATES OF MYCOBACTERIUM TUBERCULOSIS
摘要
Abstract. The data proving low probability of observing Biofilm Formation (BF) by contemporary clinical strains of M. tuberculosis growing on liquid medium in vitro are discussed. A hypothesis about the role of MDR/XDR development hindering BF production was proposed. It was found that strains capable of producing BF grow on Lewenstein–Jensen medium generated R-form specific colonies shaped as a disk with a convex center, “UFO-colonies”. Sixty seven “UFO”- strains were investigated to BF production, resistance to antibiotics and their belonging to the main epidemics clusters of the Beijing genotype (CC1 and CC2-W148). It was shown that MDR/XDR strains were also capable of BF production that, however, was remarkably more frequent in strains of CC1 and CC2-W148 genotypes. Thus, it was hypothesized that BF production might potentially influence an outcome of chronic forms of TB-infection.
435-440
GENETIC DIVERSITY OF MYCOBACTERIUM AVIUM subsp. HOMINISSUIS STRAINS ISOLATED IN ITALY BASED ON VNTR LOCI ANALYSIS
摘要
Abstract. Background. Mycobacterium avium subsp. hominissuis (MAH) is an important pathogen responsible for most of the human-associated nontuberculous mycobacteria infections. Over the past few decades the incidence of MAH infections is increasing in Italy, as in many countries worldwide. The present study is aimed to elucidate the genetic characteristics of MAH strains isolated from human patients using VNTR typing and to show the genetic relatedness among them.
Methods. The genetic diversity of 108 human isolates of MAH was determined by VNTR analysis targeting 8 loci, coded 32, 292, X3, 25, 3, 7, 10 and 47. Results. The VNTR analysis revealed 25 distinct VNTR patterns; of these, 13 patterns were unique, while 12 patterns were shared by 2 or more isolates, thus yielding 12 clusters including a total of 95 isolates. The discriminatory power of our VNTR analysis yielded an HGDI of 0.990, indicating that VNTR typing has an excellent discriminatory power. No association of a particular VNTR pattern with a particular clinical feature, such as the disseminated, pulmonary or extrapulmonary type of infection, was observed. Minimum spanning tree analysis showed that 21 VNTR patterns, occurring either as clustered or unique isolates, differed from the nearest one for one allelic variation.
Conclusions. The results obtained through the VNTR analysis showed that most MAH strains displayed a close genetic relationship. This high phylogenetic proximity of the VNTR loci over a long time period supports the concept that the MAH genotype is highly homogeneous in our geographical area, suggesting the hypothesis of the presence of possible sources of infection and transmission pathways at the local level.
441-446
RETROSPECTIVE ANALYSIS OF SLOVENIAN MYCOBACTERIUM AVIUM COMPLEX AND MYCOBACTERIUM ABSCESSUS COMPLEX ISOLATES AND MOLECULAR RESISTANCE PROFILE
摘要
Abstract. Mycobacteria belonging to Mycobacterium (M.) avium complex (MAC) and M. abscessus complex (MABSC) are the most frequent causes of mycobacteriosis in the world. In the last few years MAC and MABSC taxonomy was rapidly changing due to new molecular methods conveying the possibility to differentiate between species. New techniques are able to identify M. chimaera that was previously recognized as M. intracellulare and also differentiate subspecies of MABSC. Due to their natural habitat, non-tuberculous mycobacteria (NTM) are constantly exposed to various concentrations of antimicrobial drugs and other chemicals and consequently they had developed different mechanisms of resistance. Macrolides and aminoglycosides are frequently used drugs to treat MAC and MABSC infections. The aim of our nation-wide survey was to obtain information about MABSC subspecies prevalence in Slovenia and to assess the percentage of misidentifications of M. chimaera isolates as M. intracellulare in the past. Moreover, the purpose of our study was to reveal, which of the two species M. intracellulare or M. chimaera is clinically more relevant in Slovenia. Further, the aim of the study was to detect mutations in erm(41), rrl and rrs genes, which are known to convey macrolide resistance (erm(41) and rrl) and aminoglycoside resistance (rrs). One hundred and thirty-two Slovenian mycobacterial isolates obtained from the National Mycobacterial Collection that belong to MAC and MABSC were analysed. GenoType NTM-DR was used to differentiate M. intracellulare from M. chimaera and subspecies of MABSC. Our results showed that 48% of previously identified M. intracellulare isolates were actually M. chimaera isolates and that M. abscessus subsp. abscessus was the most frequent subspecies of MABSC. Most of the MABSC isolates carried the inducible macrolide resistance genes (erm(41) and rrl), however none of the isolates of MAC and MABSC had mutations in rrs genes for aminoglycoside resistance.
447-451
CURRENT POSSIBILITIES AND POTENTIAL DEVELOPMENT OF MOLECULAR ENTEROVIRUS SURVEILLANCE. EXPERIENCE OF RUSSIAN FEDERATION
摘要
Abstract. Enteroviruses are small RNA viruses, which are ubiquitous and commonly cause outbreaks with various clinical manifestations. In 2006, the Program on enterovirus surveillance was approved in the Russian Federation. Over the last years, molecular-biological and bioinformatics methods for enterovirus epidemiology studies have been developed both in Russia and worldwide. Currently, identification of enteroviruses is carried out by analyzing nucleotide sequence of the full-length VP1 genome region (ca. 900 nt). Routinely, it is sufficient to obtain a partial VP1 genome region sequence (ca. 300 bp) for enteroviruse verification in most cases; however, a more stringent type criterion of 80% sequence identity should be used compared to the 75% sequence identity cut-off for the complete VP1 genome region. Further sequence analysis may be performed by using Bayesian phylogenetic methods, which allow using molecular clock to trace outbreak emergence. Enteroviruses accumulate about 0.5–1% nucleotide substitutions per year. Therefore, a short genome fragment may be used to analyze virus phylodynamics at the level of international transfers and circulating virus variants. On a shorter timescale, a full-length VP1 genome region or a complete genome sequence are preferred for investigating molecular epidemiology, because a short sequence allows to reliably distinguish not more than 1–2 transmission events per year. Thus, determining enterovirus sequences for full-length VP1 genome region or full-genome sequence is preferred for examining viral outbreaks. It is increasingly apparent that analyzing available enterovirus nucleotide sequences reveals limitations related to uneven surveillance efficacy in various countries and short length of genome fragment measured in routine control. As a result, a proper global-scale analysis of enterovirus molecular epidemiology remains problematic. Over the last 20 years, the number of available enterovirus nucleotide sequences increased by hundred times, but understanding emergence of enterovirus infection outbreaks remains limited. Further development of enterovirus surveillance would require new methods for sewage monitoring, affordable high-throughput sequencing and harmonization of global surveillance systems.
452-464
IMPLEMENTATION OF THE WORLD HEALTH ORGANIZATION WESTERN PACIFIC REGIONAL PLAN OF ACTION FOR MEASLES ELIMINATION
摘要
Abstract. The Western Pacific Region (WPR) is comprised of 37 countries such as China, Japan, Mongolia, Republic of Korea, The Socialist Republic of Vietnam, Papua-New Guinea, Australia, including Pacific Island Countries and Territories (21 countries of PICTs, approx. 3 million people) etc., with a population of 1.85 billion people. Among them, China is the largest and most populous (1.3 billion people) country of the Region. Large measles outbreaks were documented to occur in the Region. In 2003, the Regional Committee announced officially about the WPR action plan on measles elimination 2005, which, however, failed. Since 2012, WPR countries joined the WHO 2012–2020 Global Measles and Rubella Strategic Plan performing a routine measles vaccination (national immunization schedule) or within Expanded Programme on Immunization (EPI). Basically, a two-dose immunization strategy is followed in the WPR countries. Since 2002, measles supplementary immunization activities (SIAs) in children were conducted in the following countries: Japan, Laos, Vietnam, Philippines, Mongolia, Cambodia, Papua New Guinea, and China. Starting from 2005, measles management was considerably improved, demonstrating by 2012 decreased measles incidence rate down to 5.9 cases per million population. In last years, a decreased measles immunization coverage in decreed population groups was noted in the WPR countries that resulted in 2013–2015 measles epidemic involving almost all regional countries. In particular, in China measles incidence rate was 19.6 cases per million population, whereas in the Vietnam Papua New Guinea and Philippines it progressively increased reaching 182.8, 345.9 and 548.0 cases per million population, respectively. Early children not vaccinated according to schedule, adolescents and young adults dominated among measles patients. It was found that measles outbreaks were due to missed vaccination and increased level of vulnerability to measles. Children under one, adolescents and young adults who did not receive a two-dose measles vaccination were in risk group. Analyzing WPR measles epidemiology demonstrated that refusal of parents to vaccinate children, poor knowledge of advantages related to vaccination, insufficient immunization coverage in immigrants, travelers, subjects changing place of residence, workers of healthcare and educational facilities require special attention. In 2017–2018 season, the following measles genotypes were found in the WPR: D8 — Australia, New Zealand, Republic of Korea, Singapore, Japan; Н1 — China; В3 — Philippines, Australia and Japan; D9 — Singapore, Australia, Macau (China), Malaysia and Japan, Н2 strains endemic in Vietnam. According to the WHO, measles endemic transmission has been successfully interrupted; Australia, Macau, Mongolia and Republic of Korea are being verified to eliminate measles; Hong Kong (China) and Singapore (based on available information) are ready to verify measles elimination. Thus, in the Western Pacific Region measles elimination is achievable after solving current issues such as increasing and maintaining high-level routine vaccination and conducting measles supplementary immunization campaigns in epidemically important contact clusters.
465-472
SUMMARY OF INFLUENZA AND OTHER RESPIRATORY VIRUSES DETECTED AND CHARACTERIZED IN RUSSIA DURING 2017–2018 SEASON
摘要
Abstract. The influenza season 2017–2018 started significantly later compared to the five previous seasons. Influenza epidemic lasted for 12 weeks (weeks 6–17), was of moderate intensity and 10,4% of the population of the country was involved with children aged 0–2 and 3–6 years being the most affected groups as usually. The average hospitalization rate of patients with ILI and ARI was 2,6% and was the highest in infants aged 0–2 years (5,4%). The number of influenzaassociated deaths was two times higher this season compared to 2016–2017 which can be attributed to the circulation of A(H1N1)pdm09 viruses that still is the major cause of lethal influenza outcomes in the country. A total 72 759 patients were investigated by RT-PCR in 55 collaborating RBLs. Laboratory confirmed influenza (LCI) was detected in 12 149 (20.7%) cases, of which 39.3% were influenza A(H1N1)pdm09 viruses, 29.6% were A(H3N2) and 31.1% influenza B (Yamagata lineage) viruses. The first cases of influenza viruses were detected at the very beginning of the season (weeks 40–45.2017), however a distinct increase in the rate of detection was registered only from the week 2.2018 with the peak on the week 13–14.2018 and subsequent gradual decline up to the end of the season. The certain differences in the etiology of morbidity between Federal Districts were registered. The impact of influenza and other ARI agents in different stage of epidemic was determined. In the pre-epidemic period, the incidence growth was occurred mainly due to ARI agents (about 32,7%), especially due to rhinoviruses (RhV) and RSV (10.2 and 8.0% cases, respectively) while LCI were registered in 3.4% only. During the epidemic, the rate of LCI detection increased up to 29.2% at simultaneous decrease in frequency of parainfluenza, adenovirus, bocavirus, coronavirus and, especially, rhinoviruses, to a lesser extent RSV infection. In the post-epidemic period, the role of influenza A(H1N1)pdm09, A(H3N2) and В viruses decreased up to 6.1; 6.9 and 3.6%, respectively, with increase of rhinoviruses (9.5% of diseases). Genetic analysis of influenza A(H1N1)pdm09 and A(H3N2) viruses circulating in 2017–2018 season showed that all analyzed viruses by the structure of surface genes encoding antigenic determinants, in difference from influenza B viruses, corresponded to the vaccine strains recommended by WHO for the Northern Hemisphere for 2017–2018 epidemic season. However, significant changes in the internal genes of circulating viruses were revealed. The control of the susceptibility of 316 influenza A and B viruses to antiviral drugs showed that the absolute majority of them (99.7%) retained their susceptibility to neuraminidase inhibitors.
473-488
NEW OPPORTUNITIES TO IDENTIFY AND TYPE STAPHYLOCOCCUS spp. BY USING MALDI-TOF MASS SPECTROMETRY
摘要
Abstract. Mass spectrometry profiles of microorganisms obtained by time-of-flight matrix-associated laser desorption/ionization (MALDI-TOF) mass spectrometry are a source of information about peptide profiles can be used for microbial identification and typing. A variety of technical and bioinformational solutions complicate developing of a united mass-spectro-profile database. Staphylococcus spp. strains are good studied objects for identification by MALDI-TOF mass spectrometry, frequently resulting in nosocomial infections, especially in immunocompromised patients. Rapid differentiation of nosocomial, multiresistant and highly virulent isolates of Staphylococcus spp. Allows to reduce the lethality in weakened and immunocompromised patients. The study was aimed at assessing comparability and reproducibility of identification and typing results for Staphylococcus spp by MALDI-TOF mass spectrometry. Comparing 292 Staphylococcus spp. isolates in clinical specimens obtained fron the multidisciplinary hospital at the NWSMU im. I.I. Mechnikov was carried out by using MALDI-TOF mass spectrometer BactoSCREEN ID (Litech, Russia) and Bruker Biotyper 3.1 (Bruker GmbH, Germany). Comparability of Staphylococcus spp. identification showed that 95.9%; 12 isolates (4.1%) by “Bruker Biotyper 3.1” and 3 isolates (1.1%) by using “BactoSCREEN ID” were incorrectly identified. Repeated identification leveled the differences between the systems used. In addition, it was shown that the method of protein extraction did not affect reliability of Staphylococcus spp. species identification by using databases (÷2, p > 0.05) compared to intraspecific typing (÷2, p < 0.0001). Using different extraction protocols showed that Staphylococcus spp. mass-spectra differed by peak intensity level within the mass range up to 4000 m/z, 5300±600 m/z and 6500±500 m/z, as well as higher than 7000 m/z. Peaks of low-molecular weight peptides were detected under full protein extraction compared to sample preparation on plate extraction. To develop a unified protocol for mass-spectrometry profile processing, a reliability of the basic statistical variables (mode, median, maximum, minimum and arithmetic mean) was evaluated. Analysis of the median mass spectrometry profiles is recommended for Staphylococcus spp. intraspecific typing by using MALDI-TOF mass spectrometry as the most reproducible and consistent approach. As a result, two systems for MALDI-TOF mass spectrometry reliably identify Staphylococcus spp., but standardization of sample preparation and bioinformation analysis is required for Staphylococcus spp. typing.
489-496
TIME-KILL ASSAY: AN EFFICACY OF SYNERGY BETWEEN CARBAPENEMS AND CLODRONIC ACID
摘要
Abstract. Currently, a search for augmenting antibiotics activity is still crucial due to elevated frequency of detecting carbapenem-resistant Gran-positive bacterial isolates. To resolve this, it might be reasonable to combine carbapenems metal-â-lactamase (MâL) inhibitors. Unfortunately, no MâL inhibitors approved for treatment of carbapenem-resistant infections are currently available. Pathogenic bacteria may survive antibiotic attack, exert tolerance and persistence accompanied with the ongoing infectious process. In connection with this, determining dependence between antimicrobialrelated bactericidal effect and exposure time on microbes at 4, 8, 12 and 24 hours after the onset, a so called time-kill assay, is necessary. A synergy between both agents was noted upon reduced microbial population by ≥ 3 log10. A checkerboard array followed by seeding the microplate well contents onto a dense nutrient medium at various time points were used to assess a synergistic efficacy of carbapenems applied together with clodronic acid against MâL-producing VIMgenotype P. aeruginosa 532/14 clinical isolate obtained from patients with infectious complications (minimal inhibitory concentrations [MIC] for imipenem or meropenem were 512 μg/ml), microbial burden 106 CFU/ml. Optical density was measured at two wavelengths (490 and 630 nm) in ELx800 reader, within 4–24 hour exposure time to determine time of logarithmic growth phase emerging in test culture. It is noteworthy that magnitude of optical density is a difference between two bichromatic measurements resulting in remarkably reduced inaccuracy due to scratches or fingerprints left on the plate. It was found that clodronic acid exhibited a synergic bactericidal effect with carbapenems against a clinically resistant MâL-producing VIM-genotype P. aeruginosa 532/14 strain. Upon that, imipenem-related antimicrobial activity was evident as early as 8 hours after the onset decreasing cell growth down to 1.4 log10 compared to control, whereas 12 hours later it resulted in total inhibition of test strain by decreasing growth of the test strain by 6 log10. Meropenem in combination with clodronic acid showed a more pronounced activity: complete absence of P. aeruginosa 532/14 growth by 8 hours of incubation, growth suppression by 3.2 log10, which reached 6 log10 12–24 hours after the onset. Time-kill assay allows to identify efficient combinations of carbapenems and MâL inhibitors, which is of great importance for increasing therapeutic efficacy of patients with severe purulent-septic complications.
497-502
RESULTS AND DIRECTIONS OF ACTIVITIES TO ENSURE THE EPIDEMIOLOGICAL SAFETY OF THE POPULATION IN MODERN CONDITIONS
FEATURES OF HIV EPIDEMIC SITUATION AMONG CHILDREN AND TEENAGERS OF THE FAR EASTERN FEDERAL DISTRICT
504
MODERN CHARACTERISTICS AND TENDENCIES OF DIARRHEAL INFECTIONS EPIDEMIC PROCESS IN RUSSIA
504
ON THE TIMELINESS OF VACCINATION IN CHILDREN’S OUTPATIENT DEPARTMENT
504-505
REGISTRATION OF DYSENTERY SONNEI CASES IN SPECIALIZED MEDICAL INSTITUTIONS OF THE LENINGRAD REGION
505
ZIKA FEVER IN THE WORLD AND THE RISK OF ITS DISTRIBUTION IN THE RUSSIAN FEDERATION
505-506
MODERN PROBLEMS OF INFECTIOUS DISEASES PREVENTION IN PUBLIC HEALTH OF REPUBLIC OF GUINEA
506
FECAL-ORAL MECHANISM IN THE GROUP AND EPIDEMIC STRUCTURES ON THE TERRITORY OF THE ROSTOV REGION WITHIN 10 YEARS
506
THE CHARACTER OF MICROBIOTA IN THE INTENSIVE CARE UNIT OF THE CHILDREN’S HOSPITAL AND ITS EPIDEMIOLOGICAL SIGNIFICANCE
506-507
ETHICS OF VACCINATION AS THE CRITERIA OF THE SCIENTIFIC AND HUMANISTIC APPROACH
507
ETHICAL CONSIDERATION IN CONCEPTION OF INFECTIOUS DISEASES ERADICATION
507-508
EPIDEMIOLOGICAL CHARACTERISTICS, ETIOLOGICAL STRUCTURE AND MODERN METHODS OF DETECTION OF PATHOGENS OF ACUTE INTESTINAL VIRAL INFECTIONS IN ORGANIZED GROUPS
508
COMPLIANCE OF HEALTH CARE WORKERS WITH VACCINATION AS THE FACTOR OF FORMATION OF POSITIVE ATTITUDE TOWARDS VACCINATION IN THE POPULATION
508
CLINICAL-EPIDEMIOLOGICAL CHARACTERISTIC OF THE INFLAMMATORY BOWEL DISEASES IN SAINT PETERSBURG
508-509
THE USE OF CORRELATION ANALYSIS ON THE EXAMPLE OF INFLUENZA VACCINATION ON THE TERRITORY OF THE ROSTOV REGION
509
EPIDEMIOLOGICAL CHARACTERISTICS OF INCIDENCE OF CHRONIC VIRAL HEPATITIS B INFECTION AMONG HEALTHCARE WORKERS IN ST. PETERSBURG IN 2013–2017
509-510
THE PREVALENCE AND MOLECULAR EPIDEMIOLOGY OF STENOTROPHOMONAS MALTOPHILA IN THE INTENSIVE CARE UNITS
510
MODERN METHODS OF MOLECULAR DIAGNOSTICS OF INFECTIOUS DISEASES
GENOMIC DIVERSITY OF NON-TOXIGENIC VIBRIO CHOLERAE EL TOR STRAINS AND METHOD FOR DIFFERENTIATION OF CHOLERA VIBRIOS WITH DIFFERENT EPIDEMIC SIGNIFICANCE, USING PCR
511
DETECTION AND ANALYSIS OF CRISPR-CAS SYSTEMS IN PLASMIDS OF DIFFERENT BACILLUS THURINGIENSIS STRAINS
511
INDEL TYPING OF VIBRIO PARAHAEMOLYTICUS STRAINS ISOLATED DURING OUTBREAKS IN THE RUSSIAN FEDERATION
511-512
EXPRESSION OF RECOMBINANT NS1 PROTEINS OF WEST NILE, DENGUE AND ZIKA FEVER VIRUSES IN NICOTIANA TABACUM FOR FUTURE USE IN DIAGNOSTICS
512
WHOLE-GENOME SEQUENCING AS A TOOL FOR COMPREHENSIVE ASSESSMENT OF THE PATHOGENIC POTENTIAL OF ANCIENT ARCTIC MICROBIOMES
512-513
THE RESULTS OF THE RESEARCH OF USING A COMMERCIAL KIT FOR DETENTION THE RABIES VIRUS`S RNA IN THE COURSE OF EVALUATION OF THE INFECTION OF THE FIELD MATERIAL
513
COLLISION OF CRISPR-CAS SYSTEMS WITH THE POTENTIAL OF VIRULENCE OF ESCHERICHIA COLI STRAINS THAT PRODUCE SHIGA-TOXINS
513
NGS CAPABILITIES FOR THE STUDY OF ENTEROAGGREGATIVE E. COLI
513-514
ALGORITHM OF EXPRESS LABORATORY DIAGNOSTICS IN THE STUDY OF DIPHTHERIA
514
MODERN LABORATORY DIAGNOSTICS OF ESСHERICHIOSIS
514-515
COMPARISON OF PHENOTYPIC AND MOLECULAR-GENETIC PROPERTIES OF THE STRAINS NEISSERIA MENINGITIDIS ISOLATED FROM PATIENTS WITH GENERALIZED FORMS OF MENINGOCOCCAL INFECTION AND CARRIERS
515
MOLECULAR TYPING IN RESEARCH OF EPIDEMICAL CHOLERA MANIFESTATION
515
PCR FOR DIAGNOSIS OF GONOCOCCAL INFECTION: PANACEA OR ESCAPE FROM REALITY
515-516
EXPERIENCE OF EXPANDED PRIMER SET USING FOR DETECTION OF THE PATHOGENIC POTENTIAL OF ESCHERICHIA COLI
516
HEPATITIS B VIRUS IDENTIFICATION IN THE ENSURING INFECTIOUS SAFETY OF BLOOD TRANSFUSIONS
516
THE USE OF RAPD-PCR FOR GENOTYPING OF S. ENTERITIDIS ISOLATED DURING THE OUTBREAK
517
A NEW VISION AT THE IDENTIFICATION OF THERMOTOLERANT CAMPYLOBACTERS
517
IDENTIFICATION OF ROTAVIRUS IAND E-GENOTYPES BY MULTIPLEX PCR METHOD
517-518
CXCL10 GENE PROMOTER POLYMORPHISM A-1447G MODULATES PROTEIN EXPRESSION IN SERUM AND ASSOCIATED WITH INVASIVE ASPERGILLOSIS IN FEMALE ONCOHEMATOLOGICAL PATIENTS
518
DEVELOPMENT OF A PANEL OF MONOCLONAL ANTIBODIES FOR STUDYING OF LOCAL PRODUCTION OF CYTOKINES IN CHRONIC RHINOSINUSITIS
518
ISLAND RND FOUND IN A STRAIN OF VIBRIO CHOLERAE ISOLATED IN THE RUSSIAN FEDERATION
519
APPLICATION OF A COMPLEX OF METHODS IN LABORATORY DIAGNOSTICS OF WEST NILE FEVER
519
THE USE OF MOLECULAR GENETIC METHOD TO DETERMINE THE ETIOLOGY OF COMMUNITYACQUIRED PNEUMONIA IN SERVICEMEN
519
VIRAL INFECTIONS MANAGED BY MEANS OF VACCINATION AT THE STAGE OF DESTRUCTION AND ELIMINATION
PROCESS FOR IMPLEMENTING POLIOVIRUS ENVIRONMENTAL SURVEILLANCE IN COTE D’IVOIRE FROM DECEMBER 2016 TO DECEMBER 2017
520
ANALYSIS OF MEASLES CASES IN CHILDREN DURING THE OUTBREAK IN MONGOLIA, 2015
520
DETECTION OF PRIMATE ERYTHROPARVOVIRUS 1 DNA IN BLOOD SERUM OF PATIENTS WITH ERYTHEMA
520
STUDY ON HERD IMMUNITY AGAINST INFLUENZA VIRUS AMONG THE POPULATION OF ALMATY REGION IN 2017–2018
521
CIRCULATION OF INFLUENZA VIRUSES AMONG HUMANS AND SWINE IN THE REGIONS OF NORTHERN AND WESTERN KAZAKHSTAN IN 2017–2018
521
CHARACTERIZATION OF ENTEROVIRUSES BY NEXT-GENERATION SEQUENCING
521
EPIDEMIC RISE OF INFLUENZA IN ST. PETERSBURG IN JANUARY-MARCH 2018
521-522
MEASLES AND RUBELLA IN NORTH-WEST REGION OF RUSSIA AT THE STAGE OF ELIMINATION
522
EVOLUTION OF THE VP1 REGION TYPE 2 VACCINE-DERIVED POLIOVIRUS SHEDDING FROM AN IMMUNOCOMPROMISED ALGERIAN CHILD
522-523
EPIDEMIOLOGICAL CHARACTERISTICS OF MEASLES
523
INTRATYPIC DIFFERENTIATION OF POLIOVIRUSES IN THE INTER-POLIO LABORATORY OF THE INSTITUT PASTEUR OF COTE D’IVOIRE IN 2002–2017: WHAT EVOLUTION?
523
EPIDEMIOLOGICAL MONITORING OF POLIOMYELITIS IN THE CENTRAL AFRICAN REPUBLIC FROM 2004 TO 2017 AND IMPLEMENTATION OF POLIOVIRUS ENVIRONMENTAL SURVEILLANCE IN BANGUI IN 2017
523-524
CIRCULATION OF THE EPIDEMIC VARIANT OF NOROVIRUS GII.4_SYDNEY2012 IN NIZHNY NOVGOROD, RUSSIA
524
INFLUENCE OF VAGINAL MICROBIOTA ON THE ACTIVITY OF HUMAN PAPILLOMAVIRUS
524
EMERGENCE OF VACCINE-DERIVED POLIOVIRUSES DURING EBOL A VIRUS DISEASE OUTBREAK IN GUINEA, 2014–2015
525
ENTEROVIRUS INFECTION IN THE RUSSIAN FEDERATION IN 2008–2018
525
MEASLES IN YEKATERINBURG: THE HISTORICAL PATH FROM THE PERIOD BEFORE VACCINATION TO THE STAGE OF ELIMINATION OF THE INFECTION
526
GENERATION AND CHARACTERIZATION OF GENETIC REASSORTANTS BETWEEN POTENTIALLY PANDEMIC VIRUSES (A/H9N2 OR A/H5N8) AND THE A/HONG KONG/1/68/162/35 (H3N2) MASTER DONOR VIRUS
526
FURTHER DEVELOPMENT OF “IgY-TECHNOLOGY”: AN ELISA SYSTEM BASED ON SPECIFIC ANTIBODIES FROM EGG YOLKS AS A SURROGATE VARIANT OF THE NEUTRALIZATION TEST
526-527
REALIZATION OF POLIO ERADICATION PROGRAM IN THE RUSSIAN FEDERATION: CURRENT STATUS AND CHALLENGES OF THE PERIOD AFTER CERTIFICATION OF THE EUROPEAN REGION, 2003–2017
527
ENVIRONMENTAL AND HUMAN SURVEILLANCE OF POLIOVIRUSES AND OTHER ENTEROVIRUSES IN MADAGASCAR. IMPACT OF THE TRIVALENT TO BIVALENT ORAL POLIO VACCINE SWITCH
527
ENTEROVIRUSES ISOLATED FROM CHILDREN FROM MIGRANTS’ FAMILIES IN THE NORTH-WEST OF RUSSIA
528
DYNAMICS OF MORBIDITY OF THE WEST NILE FEVER IN THE ASTRAKHAN REGION
528
DETECTION OF PARVOVIRUS INFECTION MARKERS IN RISK GROUPS
528-529
CYTOKINE PROFILE IN ADULTS WITH RESPIRATORY SYNCYTIAL VIRAL INFECTION
529
SURVEILLANCE OF POLIOMYELITIS AND ACUTE FLACCID PARALYSIS IN THE SOUTH OF THE RUSSIAN FEDERATION IN 2013–2017
529
OPTIMIZATION OF EXPRESSION, PURIFICATION, AND STABILIZATION CONDITIONS FOR FLG-HA2-4M2E, A RECOMBINANT PROTEIN IN UNIVERSAL INFLUENZA VACCINE
530
THE ROLE OF MORAXELLA CATARRHALIS IN THE DEVELOPMENT OF COMPLICATIONS AFTER INFLUENZA AND OTHER ACUTE RESPIRATORY DISEASES
530
THE IMPORTANCE OF PATHOGENICITY FACTORS OF SOME SPECIES OF STAPHYLOCOCCUS, STREPTOCOCCUS AND KLEBSIELLA IN DETERMINING THEIR ETIOLOGICAL ROLE IN THE DEVELOPMENT OF INFLAMMATORY PROCESSES OF THE RESPIRATORY TRACT
530-531
PARVOVIRUS INFECTION: DISSEMINATION, MEDICAL-SOCIAL SIGNIFICANCE
531
SENSITIVITY OF 2018 KAZAKHSTAN INFLUENZA TYPE B VIRUSES TO ANTIVIRAL DRUGS
531
EPIDEMIOLOGICAL ANALYSIS OF MEASLES OUTBREAK IN GUINEA 2017–2018
532
ASSESSMENT OF THE RISK OF MEASLES INFECTION IN HOSPITAL
532
DEVELOPMENT OF PROTOTYPE OF UNIVERSAL INFLUENZA VACCINE BASED ON LIVE ATTENUATED INFLUENZA VACCINE VIRAL VECTOR
532-533
CIRCULATION OF COXSACKIEVIRUS A IN HANDFOOT-MOUTH DISEASE IN SOUTHERN VIETNAM, 2015–2016
533
EPIDEMIOLOGY OF ADENOVIRAL INFECTION IN ST. PETERSBURG
533
CHALLENGES FOR POLIO ERADICATION. RISK OF RE-EMERGENCY OF INFECTION IN POLIO FREE COUNTRIES
533-534
ROLE OF DIFFERENT TYPES OF ENTEROVIRUSES IN ETIOLOGY OF INFECTION ON CERTAIN TERRITORIES OF RUSSIA
534
MOLECULAR-GENETIC CHARACTERISTICS OF THE COXSAKIE A10 ENTEROVIRUS THAT WAS CIRCULATING IN THE CONSTITUENT ENTITIES OF THE RUSSIAN FAR EAST
534-535
DISTRIBUTION OF ROTAVIRUS G-, P-, I-, AND E-GENOTYPES IN NIZHNY NOVGOROD, RUSSIA
535
DIAGNOSIS OF CYTOMEGALOVIRUS AND PARVOVIRUS B19 INFECTIONS IN SPECIAL GROUPS OF PATIENTS
535
IMPROVEMENT OF TECHNOLOGY OF PRODUCTION OF HERPETIC VACCINE, CULTURAL, INACTIVE
535-536
IMMUNIZATION WITH UNIVERSAL INFLUENZA VACCINE ENHANCES IMMUNE RESPONSE TO SUBSEQUENT INFECTION
536
FEATURES OF POPULATION IMMUNITY AGAINST MEASLES AND RUBELLA VIRUSES. WHY DO ADULTS SUFFER?
536
RISK FACTORS FOR SARI AND INFLUENZA VACCINE EFFECTIVENESS IN SENTINEL SURVEILLANCE SYSTEM IN RUSSIA, THE SEASON 2017–2018
537
RESULTS OF MOLECULAR DETECTION AND CHARACTERIZATION OF INFLUENZA AND OTHER RESPIRATORY VIRUSES IN RUSSIA, SEASON 2017–2018
537
PROSPECTS FOR MONOCLONAL ANTIBODIES USING IN DIFFERENTIAL DIAGNOSIS OF ADENOVIRUS INFECTION
537-538
THE ROLE OF MOLECULAR-GENETIC RESEARCH IN THE SYSTEM OF EPIDEMIOLOGICAL SURVEILLANCE OVER ENTEROVIRUS INFECTION IN THE RUSSIAN FAR EAST AND SIBERIA
538
CONTROL OF INFLUENZA VIA VACCINES: CHALLENGES AND PERSPECTIVES AS VIEWED BY VARIOUS STAKEHOLDERS
538
CROSS-ANTIGENIC AND IMMUNOGENIC FEATURES OF CANONICAL AND NEW GENOGROUPS OF ENTEROVIRUS 71
538-539
CLINICAL-LABORATORY CHARACTERISTICS OF INFLUENZA INFECTION IN HOSPITALIZED ADULT PATIENTS IN THE EPIDEMIC SEASON 2017–2018
539
VACCINE PROPHYLAXIS, DIAGNOSTICS AND GENOTYPES OF MUMPS (EPIDEMIC PAROTITIS) VIRUS
539-540
INFLUENCE OF THE NEWCASTLE DISEASE VIRUS ON SOME INDICES OF CELL-MEDIATED IMMUNITY IN TUMOR-BEARING RATS
540
THE EFFECT OF PARVOVIRUS B19 INFECTION ON RESULTS OF CHEMOTHERAPY IN PATIENTS WITH LYMPHOMA
540
ASSOCIATION BETWEEN HERPES VIRUS INFECTION AND INDICATORS OF OXIDATIVE STATUS OF TUMOR TISSUE IN GASTRIC CANCER
540-541
ZOONOTIC AND PARASITIC INFECTIONS: CLINICAL, EPIDEMIOLOGICAL AND LABORATORY ASPECTS
PCR ANALYSIS IN THE REAL TIME REGIMEN AS A LONG-TERM METHOD FOR LABORATORY DIAGNOSIS OF RICKETTSIOSIS
542
LESIONS OF THE GASTROINTESTINAL TRACT IN SCHOOLCHILDREN INVASED BY LAMBLIA
542
CLINICAL-EPIDEMIOLOGICAL AND LABORATORYINSTRUMENTAL ASPECTS OF NON-ERYTHEMATOUS FORM IN PATIENTS WITH TICK-BORNE BORRELIOSIS
542-543
DETECTION OF GENETIC MARKERS OF TICK-BORNE RICKETTSIOSIS WITH THE PCR
543
DATABASE OF LEPTOSPIRA PROTEIN SPECTRA FOR MASS-SPECTROMETRY IDENTIFICATION
543-544
INFORMATION TECHNOLOGY APPLICATION FOR NATURAL FOCI INFECTIONS MONITORING AND PREDICTION
544
ANALYSIS AND FORECASTING INCIDENCE OF BRUCELLOSIS IN THE REPUBLIC OF DAGESTAN
544
THE DYNAMICS OF TICK VECTORS INFECTION RATE WITH IXODIC TICK BORRELIOSIS CAUSATIVE AGENTS IN KHABAROVSK REGION DURING THE EPIDEMIC SEASON OF 2017–2018
544-545
PATHOGENS, PESTICIDE RESISTANCE AND GENETIC DIVERSITY OF HUMAN HEAD LICE
545
WHOLE GENOME-BASED CHARACTERIZATION OF COXIELLA BURNETII STRAINS ISOLATED IN RUSSIAN FEDERATION
545
INTERNATIONAL COLLABORATIVE PROJECT ON TICK-BORNE ENCEPHALITIS IN THE BARENTS REGION
546
IS THERE A TRANSOVARIAL TRANSMISSION OF TAIGA TICK (IXODES PERSULCATUS Sch.) AND THE SHEEP TICK (IXODES RICINUS (L.)) THE CAUSATIVE AGENT OF IXODID TICK-BORNE BORRELIOSIS (BORRELIA BURGDORFERI s.l.)?
546
FEATURES OF BACILLUS ANTHRACIS IDENTIFICATION BY MALDI-TOF MS
546-547
ETIOLOGICAL CHARACTERISTICS OF MALARIA AND PREVALENCE OF HEMOGLOBINOPATHIES IN PATIENTS IN THE REPUBLIC OF GUINEA
547
PECULIARITIES OF MASS SPECTROMETRIC ANALYSIS OF BRUCELLA S- AND L-FORMS
547-548
COXIELLA BURNETII PREVALENCE IN TICKS IN THE ULYANOVSK REGION
548
WHOLE GENOME-BASED PHYLOGENETIC DIVERSITY AND GENOMIC EPIDEMIOLOGY OF LEPTOSPIRA
548
MONITORING VECTORS OF TICK-BORNE BORRELIOSIS, HUMAN GRANULOCYTIC ANAPLASMOSIS, HUMAN MONOCYTIC EHRLICHIOSIS IN STAVROPOL REGION IN 2017
549
VARIABILITY OF THE LEVEL OF INFLUENCE OF RED VOLE POPULATIONS BY HANTAVIRUS PUUMALA IN THE REPUBLIC OF TATARSTAN IN 2015–2017
549
EPIDEMIOLOGICAL SURVEILLANCE OVER TICK-BORNE VIRAL ENCEPHALITIS IN ARKHANGELSK REGION
550
IMMUNOLOGICAL SCREENING OF LEPTOSPIROSIS IN DOGS IN ST. PETERSBURG
550
A SURVEY ON CASES OF TICK BORNE ENCEPHALITIS IN ST. PETERSBURG
550-551
COOPERATION OF ZOOLOGICAL GROUP AND THE PCR LABORATORY FOR EVALUATION OF EPIZOOTICS IN REPUBLIC OF BASHKORTOSTAN
551
THE IMPACT OF GLOBAL CLIMATE CHANGE ON THE INCIDENCE OF TICK-BORNE ENCEPHALITIS IN THE EUROPEAN PART OF THE RUSSIAN ARCTIC
551
PATHOGENETIC TREATMENT OF SEVERE P. FALCIPARUM MALARIA: APPROACHES TO OPTIMIZATION
551-552
CURRENT PROBLEMS IN DIAGNOSTICS AND TREATMENT OF STRONGULOIDIASIS
552
ANALYSIS OF POPULATIONS OF BACILLUS ANTRACIS STRAINS ON THE BASIS OF THEIR RESISTANCE TO SPECIFIC ANTHRAX BACTERIOPHAGES
552
COMPARATIVE CHARACTERIZATION OF SUBCULTURES ISOLATED FROM A POPULATION OF BACILLUS ANTHRACIS 1 (SO) STRAIN ON THE BASIS OF PHAGE RESISTANCE TO SOME SPECIFIC ANTHRAX BACTERIOPHAGES
552-553
MODERN DIRECTIONS IN OPTIMIZATION OF RABIES SURVEILLANCE
553
YERSINIOSIS: TAXONOMY, PHYLOGEOGRAPHY, POLYMORPHISM OF PATHOGENICITY FACTORS AND SELECTIVE VIRULENCE
YERSINIA PESTIS VOLE’S STRAINS: TAXONOMY, PHYLOGEOGRAPHY, POLYMORPHISMS OF PATHOGENICITY FACTORS AND SELECTIVE VIRULENCE
554
CREATING A SPECTRA LIBRARY FOR SPECIFIC MALDI-TOF MASS SPECTROMETRY IDENTIFICATION OF YERSINIA ENTEROCOLITICA-LIKE SPECIES
554
EPIDEMIOLOGICAL AND CLINICAL PECULIARITIES OF PSEUDOTUBERCULOSIS OUTBREAKS
554-555
INTRASPECIFIC DIVERSITY OF YERSINIA PESTIS CHAPERONE/USHER SECRETION APPARATUSES
555
THE OUTER MEMBRANE PROTEIN A (ompA) OF YERSINIA PESTIS IS NOT REQUIRED FOR VIRULENCE IN MICE AND RATS
555
GENETIC DETERMINANTS CHARACTERISTIC FOR YERSINIA PSEUDOTUBERCULOSIS STRAINS ISOLATED FROM PATIENTS WITH FAR-EAST SCARLETT-LIKE FEVER
556
DYNAMICS OF MORBIDITY OF THE WEST NILE FEVER IN THE ASTRAKHAN REGION
556
POSSIBILITIES OF NON-INVASIVE METODS APPLICATION FOR DIAGNOSIS OF YERSINIOSIS IN CHILDREN
556-557
ONCE UPON A TIME IN THE FAR EAST: ON THE 50TH ANNIVERSARY OF THE DISCOVERY OF “REAL PSEUDOTUBERCULOSIS” AMONG HUMANS
557
MONITORING OF VACCINAL PROCESS IN HUMANS RESIDING IN THE ALTAI HIGH-MOUNTAINOUS NATURAL PLAGUE FOCUS
557
HETEROGENEITY OF POPULATIONS OF THE FLEA CITELLOPHILUS TESQUORUM ELBRUSENSIS DETECTED ON THE BASIS OF ANALYSIS OF PROTEOMIC PROFILES BY THE METHOD OF MALDI-TOF MS
558
THE GRANULOCYTES PHAGOCYTIC CAPACITY TO YERSINIA PESTIS IN BLOOD SAMPLES OF ANTIPLAGUE VACCINATED PEOPLE ACCORDING TO FLOW CYTOMETRIC ANALYSIS DATA
558
ANTI-PLAGUE VACCINATION STIMULATES THE NEUTROPHIL EXTRACELLULAR TRAPS FORMATION TO INCREASE THE YERSINIA PESTIS KILLING EFFICIENCY IN VIVO
558-559
HLA GENE POLYMORPHISM IN PERSONS VACCINATED AGAINST PLAGUE
559
WHOOPING COUGH — AN UNDERESTIMATED “ADULT” INFECTION
559
CHARACTERISTICS OF A MOBILE LABORATORY FOR MONITORING AND DIAGNOSTICS DURING EPIZOOTOLOGICAL INVESTIGATION IN THE MONGOLIAN PART OF THE TRANSBOUNDARY SAILUGEM PLAGUE FOCUS
559-560
CLONING OF THE YERSINIA PESTIS TRANSALDOLASE GENE
560
THE PRESENT EPIDEMIOLOGICAL CHARACTERISTICS OF YERSINIOSIS IN THE RUSSIAN FEDERATION
560
MALDI-TOF MASS SPECTROMETRY ANALYSIS FOR DETECTION OF THE RIBOSOMAL MARKERS TO IDENTIFY OF YERSINIA KRISTENSENII STRAINS
561
TUBERCULOSIS AND MYCOBACTERIA: MOLECULAR APPROACH
PERFORMANCE OF GENEXPERT MTB/RIF IN THE DIAGNOSIS OF EXTRAPULMONARY TUBERCULOSIS IN MOROCCO
562
ANALYSIS OF GENE MUTATIONS ASSOCIATED WITH MDR AMONG MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED IN MOSCOW REGION
562
COULD THE NEW INSIGHTS INTO PZA RESISTANCE PROVIDE ROUTE TO SHORTER MORE EFFECTIVE TB THERAPY?
562-563
IDENTIFICATION OF MUTATIONS OF RESISTANCE TO FLUOROQUINOLONES, AMINOGLYCOSIDES AND ETHAMBUTOL IN RIFAMPICIN-RESISTANT MYCOBACTERIUM TUBERCULOSIS
563
MOLECULAR TYPING OF MYCOBACTERIUM KANSASII — A GLOBAL PERSPECTIVE
563-564
GENETIC DIVERSITY OF MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS ISOLATES IN PAKISTAN
564
UPDATE ON VIRULENCE FACTORS IN MYCOBACTERIA
564
GENOTYPING OF MULTIDRUG AND PREEXTENSIVELY DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS ISOLATES FROM A HIGH INCIDENCE TB AREA IN MOROCCO
565
THE CORRELATION BETWEEN LEVELS OF PHENOTYPIC RESISTANCE AND GENOTYPIC MUTATIONS OF M. TUBERCULOSIS
565
GENOMIC EPIDEMIOLOGY OF TUBERCULOSIS: FROM WITHIN HOST EVOLUTION TO GLOBAL MIGRATION PATTERNS
566
EMERGENCE OF BEDAQUILINE RESISTANCE AFTER COMPLETION OF BEDAQUILINE-BASED DRUGRESISTANT TB TREATMENT: A CASE STUDY FROM SOUTH AFRICA
566
WHOLE GENOME SEQUENCING SHEDS LIGHT ON THE TRANSMISSION DYNAMICS OF A MULTIDRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS OUTBREAK OVER 23 YEARS IN A HIGH INCIDENCE SETTING
566-567
A 15-YEAR SPATIOTEMPORAL ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS LINEAGES 1 AND 2 IN CHIANG RAI, THAILAND
567
MOLECULAR-GENETIC METHODS OF DETECTION OF TUBERCULOSIS AND ITS DRUG RESISTANCE IN ARKHANGELSK REGION IN 2017
567-568
DETECTION OF EXTRACELLULAR MYCOBACTERIUM TUBERCULOSIS SMALL RNAs
568
TB PORTALS PROGRAM: DATA-DRIVEN MULTINATIONAL CONSORTIUM AGAINST DRUG-RESISTANT TUBERCULOSIS
568
SIMPLIFYING NGS APPROACHES TO OPTIMIZE TRACING OF TRANSBORDER SPREAD OF MYCOBACTERIUM TUBERCULOSIS
568-569
GENETIC DIVERSITY AND DRUG RESISTANCE OF MYCOBACTERIUM AVIUM IN ITALY
569
GENOTYPES OF MYCOBACTERIUM TUBERCULOSIS ISOLATES FROM DIFFERENT ORGANS OF PATIENTS WITH GENERALIZED TB AND HIV-COINFECTION
569
PHYSIOLOGICAL IMPACT OF THE EVOLUTION OF THE rpoB MUTATION
570
MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE MUTATIONS AND UNDERSTANDING OF PK/PD: TREATMENT AND CARE IMPLICATIONS
570
GENOMICS AND LOCAL ADAPTATION OF MYCOBACTERIUM AVIUM
570-571
UTILITY OF WHOLE GENOME SEQUENCING (WGS) OF MYCOBACTERIUM TUBERCULOSIS COMPLEX ISOLATES IN PRACTISE
571
MINOR GENETIC DETERMINANTS OF SECOND-LINE INJECTION DRUGS RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
571
PECULIARITIES OF THE TUBERCULOSIS, HIV AND HIV-ASSOCIATED TUBERCULOSIS INCIDENCE IN THE FAR EASTERN FEDERAL DISTRICT OF THE RUSSIAN FEDERATION
572
GLOBAL WHO POLICIES ON MOLECULAR METHODS FOR TB DIAGNOSIS
572
PREVALENCE OF NONTUBERCULOUS MYCOBACTERIUM spp. STRAINS ISOLATED FROM CLINICAL SPECIMENS AT NORTH ESTONIA MEDICAL CENTRE IN 2001–2017
572
THE INFLUENCE OF THE H2 COMPLEX ON MYCOBACTERIUM AVIUM INFECTION IN MICE
573
MYCOBACTERIUM AVIUM-TRIGGERED DISEASE: HOST GENETICS AND IMMUNITY IN MOUSE MODELS
573
EVOLUTION AND TRANSMISSION OF MYCOBACTERIUM TUBERCULOSIS RESISTANCE TO FLUOROQUINOLONES
573
EPIDEMIOLOGY OF EXTRAPULMONARY TUBERCULOSIS IN ALBANIA, 2010–2016
573-574
DETERMINANTS OF TB RELATED DEATH FROM TUBERCULOSIS PATIENTS IN THE NORTHERN THAILAND
574
CLICHES AND DOGMAS IN MOLECULAR TUBERCULOSIS RESEARCH
574-575
ANALYSIS OF SECONDARY RESISTANCE OF MYCOBACTERIUM TUBERCULOSIS TO SECOND-LINE ANTI-TUBERCULOSIS DRUGS IN CASABLANCA
575
DEVELOPMENT OF THE EXTERNAL QUALITY ASSESSMENT SCHEME FOR NON-TUBERCULOUS MYCOBACTERIA DRUG SUSCEPTIBILITY TESTING IN EUROPEAN UNION
575
BACTERIAL WGS AND HOST GENOME-WIDE SNP ANALYSIS OF TUBERCULOSIS PATIENTS IN THAILAND
576
POPULATION STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS ISOLATES FROM TB-HIV COINFECTED PATIENTS IN OMSK REGION, WEST SIBERIA, RUSSIA
576-577
LOOKING INSIDE THE FOREST: FROM CLASSICAL GENOTYPING OF MYCOBACTERIUM TUBERCULOSIS TO WHOLE GENOME SEQUENCING IN HIGH MULTIDRUG RESISTANCE SETTINGS
577
ADVANCES IN THE STUDY OF MOLECULAR BASIS OF RESISTANCE TO NEW ANTI-TB DRUGS
577
THE IMPLEMENTATION OF NEXT-GENERATION SEQUENCING FOR EPIDEMIOLOGICAL STUDIES AND DRUG RESISTANCE INVESTIGATIONS IN MICROEPIDEMICS INVOLVING PEDIATRIC TUBERCULOSIS PATIENTS
577-578
MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS IN LATVIA
578
FUNCTIONAL RELEVANCE OF MYCOBACTERIUM TUBERCULOSIS DIVERSITY: FROM GENOTYPES TO IMMUNE RESPONSES AND DISEASE SEVERITY
578-579
THE ROLE OF THE IS6110 IN MICRO- AND MACROEVOLUTION OF MYCOBACTERIUM TUBERCULOSIS LINEAGE 2
579
NGS DETERMINATION OF MYCOBACTERIAL TRANSRENAL DNA AS POTENTIAL TOOL OF CLINICAL DIAGNOSTIC
579
MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS IN KAZAKHSTAN, 2006–2018
580
NEXT-GENERATION SEQUENCING OF DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS — FIRST SLOVENIAN EXPERIENCE
580
WGS IN ROUTINE DIAGNOSTICS OF TUBERCULOSIS — PREDICTION OF DRUG RESISTANCE AND GENOTYPING
580-581
SINGLE NUCLEOTIDE POLYMORPHISMS IN hsp65 AND MACPPE12 GENES OF MYCOBACTERIUM AVIUM subsp. HOMINISSUIS
581
MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS IN ALBANIA (2006–2011)
581
THE IMPACT OF THE DELETION OF THE MMP-1 GENE ON THE EXPRESSION OF SYMPTOMS AND THE EFFECTIVENESS OF TREATMENT IN PATIENTS WITH PULMONARY TUBERCULOSIS
582
IN VITRO ACTIVITY OF BEDAQUILINE AGAINST NON-TUBERCULOUS MYCOBACTERIA
582
EMERGING OPPORUNISTIC PATHOGEN MYCOBACTERIUM ABSCESSUS IN SLOVENIA: MOLECULAR ANALYSIS OF RESISTANCE GENES COMPARED TO MIC METHOD
582-583
MOLECULAR FEATURES OF MYCOBACTERIUM TUBERCULOSIS ISOLATES FROM PATIENTS LIVING IN CLOSED CITY IN THE URAL REGION, RUSSIA
583
PREVALENCE AND DIVERSITY OF NONTUBERCULOUS MYCOBACTERIA IN DIFFERENT REGIONS OF THE RUSSIAN FEDERATION
583
MOLECULAR CHARACTERIZATION OF MYCOBACTERIUM BOVIS ISOLATES FROM CATTLE IN BULGARIA
583-584
INTERNATIONAL VALIDATION OF ANALYSIS PIPELINES FOR WHOLE GENOME SEQUENCING DATA OF MYCOBACTERIUM TUBERCULOSIS ISOLATES
584
RNA-BASED DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS
584-585
POPULATION STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS IN RUSSIAN REGIONS BORDERING EU COUNTRIES
585
DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS: FROM PHENOTYPIC MIC-ANALYSIS TO WGS FOR ROUTINE DRUG SUSCEPTIBILITY TESTING
585
MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS IN EASTERN SIBERIA AND FAR EAST
586
MOLECULAR DIAGNOSTICS OF TUBERCULOSIS: CLINICAL ASPECTS AND CHALLENGES OF IMPLEMENTATION
586-587
HIV, HEPATITIS AND OTHER SOCIALLY SIGNIFICANT INFECTIONS
THE ANALYSIS OF TRANSMITTED HIV-1 VARIANTS AMONG ACUTELY INFECTED PEOPLE WHO INJECT DRUGS USING NGS APPROACH
588
VIRAL HEPATITIS B AND C IN THE ARKHANGELSK REGION: LONG-TERM DYNAMICS OF INCIDENCE AND CROSS-SECTIONAL STUDY OF MARKERS AMONG ADULT POPULATION
588
IMMUNOPATHOGENESIS HIV AND MATHEMATICAL MODELING
588-589
CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY
589
FREQUENCY AND THE CLINICAL SIGNIFICANCE OF OCCULT HEPATITIS B VIRUS INFECTION
589
HEPATITIS A PREVALENCE AMONG CHILDREN IN BOKE AND KINDIA PROVINCES (REPUBLIC OF GUINEA)
589-590
HIGH BURDEN OF HEPATITIS B IN VIETNAM: IMPACT OF A HIGHLY HETEROGENEOUS VIRAL POPULATION
590
MOLECULAR-GENETIC CHARACTERISTICS OF THE HEPATITIS B IN THE NANAYSKY DISTRICT OF THE KHABAROVSK TERRITORY
590-591
THE OCCURENCE OF HEPATITIS C MARKERS AMONG RESIDENTS OF THE KINDIA PREFECTURE OF THE REPUBLIC OF GUINEA AND THE KHANH HOA PROVINCE OF VIET NAM
591
POLYMORPHISM THE CCR2 GENE IN THE ST. PETERSBURG POPULATION
591
RECONSTRUCTION OF RECOMBINATION SITES IN GENOMES OF GENOTYPE 2 HEPATITIS C VIRUS STRAINS USING BIOINFORMATICS METHODS
591-592
LOW HEPATITIS B VIRUS DNA BURDEN DOES NOT ALWAYS PROTECT FROM LIVER CANCER DEVELOPMENT
592
THE PREVALENCE OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WITH LOW ADHERENCE TO ANTIRETROVIRAL THERAPY IN THE LENINGRAD REGION
592
PARENTERAL VIRAL HEPATITIS IN CHILDREN IN RUSSIA, PARTICULARLY IN THE NORTHWESTERN FEDERAL DISTRICT
593
MONITORING OF LONG-TERM ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS B
593
DEVELOPMENT AND APPROBATION METHOD OF IDENTIFICATION MUTATIONS THE RESISTANCE OF THE HEPATITIS C VIRUS TO DIRECT-ACTING ANTIVIRAL AGENTS (DAAs)
593-594
THE SIGNIFICANCE OF THE HIV RESISTANCE ANALYSIS IN ANTIRETROVIRAL THERAPY
594
FORECASTING OF INCIDENCE OF HAV WITH USE OF THE SCHEDULED PLAN OF WALD
594
RISK FACTORS OF PERINATAL TRANSMISSION OF HEPATITIS C VIRUS
594-595
INFECTIOUS IMMUNOLOGY AT THE PRESENT STAGE
CREATION OF THE IMMUNOFERMENTIC TEST SYSTEM FOR DETECTING C3 COMPLEX COMPONENT WITH THE USE OF PEPTIDOGLYCAN
596
FEATURES OF THE SUBPOPULATION COMPOSITION CYTOTOXIC T-LYMPHOCYTES IN CHILDREN WITH CONGENITAL CHRONIC HEPATITIS B
596
INFLUENCE OF MONOSTRAIN AND MULTISTRAIN AUTOPROBIOTICS ON MICROBIOTA AND IMMUNITY OF RATS WITH INTESTINAL DYSBIOSIS
596-597
POTENTIAL INFLUENCE OF IMMUNOMODULATORS ON THE PRODUCTION OF INTERFERON-GAMMA AND INTERLEUKIN-10 IN LABORATORY ANIMALS VACCINATED AGAINST PLAGUE
597
NEUTROPHIL/LYMPHOCYTE DISBALANCE AS A PREDICTOR OF VAGINITIS
597-598
THE TRECs AND KRECs FREQUENCY IN THE BLOOD IN A POPULATION OF ST. PETERSBURG
598
COMPARATIVE ESTIMATION OF SENSITIVITY OF SEROLOGICAL REACTIONS FOR ESTIMATION OF IMMUNITY AGAINST THE CAUSATIVE AGENT OF TULAREMIA
598
THERAPEUTIC EFFICACY OF MONOCLONAL ANTIBODIES AGAINST LETHAL TOXIN OF BACILLUS ANTHRACIS IN A MOUSE MODEL
598-599
THE CLINICAL, IMMUNOLOGICAL AND LABORATORY PARAMETERS IN PATIENTS WITH LEPTOSPIROSIS IN ST. PETERSBURG
599
CYTOPROTECTIVE POTENTIAL OF MONOCLONAL ANTIBODIES AGAINST BURKHOLDERIA PSEUDOMALLEI
599
INNATE AND ADAPTIVE IMMUNITY CYTOKINES IN NASAL MUCOSA AND BLOOD SERUM OF ALLERGIC RHINITIS PATIENTS
600
ANALYSIS OF TOXIN-NEUTRALIZING ACTIVITY OF MOUSE MONOCLONAL ANTIBODIES AGAINST PROTECTIVE ANTIGEN OF BACILLUS ANTHRACIS
600
ANTIBIOTIC RESISTANCE OF MICROORGANISMS: CURRENT ISSUES OF DIAGNOSIS AND WAYS TO OVERCOME
THE EFFECT OF SUB-BACTERICIDAL DOSES OF ANTISEPTICS ON DNA AND PHENOTYPIC MARKERS OF VIRULENCE OF MICROORGANISMS
601
METABOLIC ACTIVITY OF PLANKTON IN COMPARISON WITH BIOFILM PHENOTYPE SOME MICROORGANISMS OF HUMAN MICROBIOTA
601
STUDY OF ANTIMICROBIAL RESISTANCE IN MEDICAL INSTITUTIONS IN CONAKRY (REPUBLIC OF GUINEA)
601-602
MICROBIOLOGICAL ASPECTS OF PURULENT SEPTIC INFECTIONS BREAKOUT INVESTIGATION IN KHABAROVSK CITY
602
SEROVAR SPECIFIC ANTIMICROBIAL SUSCEPTIBILITY OF SALMONELLA
602
PERINATAL LISTERIOSIS: THE MOUSE MODEL
603
PHENOTYPES AND GENOTYPES OF CLASSICAL AND HYPERVIRULENT KLEBSIELLA PNEUMONIAE CLINICAL STRAINS ISOLATED IN MOSCOW IN 2013–2018
603
RELATIONSHIP BETWEEN MICROORGANISMS IN THE VAGINAL BIOTOPE OF SUBFERTIL WOMEN
603-604
IMPROVEMENT OF BACTERIAL BIOFILM’S INVESTIGATION
604
EFFECT OF METAL OXIDE NANOPARTICLES ON THE EXCHANGE OF GENETIC MATERIAL BETWEEN BACTERIA
604
SONOCHEMICAL NANOSTRUCTURING OF ANTIBIOTICS IS A NEW APPROACH TO INCREASING THEIR EFFECTIVENESS AGAINST RESISTANT STRAINS
604
DEVELOPMENT OF FUNCTIONAL NANOSTRUCTURES EFFECTIVE AGAINST BACTERIA BIOFILMS INCLUDING MULTIDRUG RESISTANT BACTERIA
605
KLEBSIELLA PNEUMONIAЕ AND ITS GENES OF RESISTANCE TO BETA-LACTAMAMS IN PSYCHIATRIC HOSPITAL
605
RESISTANCE TO ANTIBIOTICS OF DIARRHEAGENIC ESCHERICHIA COLI IN PSYCHIATRIC HOSPITAL
605-606
MOLECULAR ANALYSIS OF PATHOGENS OF PARTICULARLY DANGEROUS BACTERIAL INFECTIONS: FROM THEORY TO PRACTICE
606
DIFFERENTIATION OF KLEBSIELLA spp. STRAINS FOR SENSITIVITY TO ANTIBIOTICS USING MASS SPECTROMETRY ANALYSIS MALDI-TOF
606
PATHOGENIC POTENTIAL OF COMMENSAL ESCHERICHIA COLI ISOLATED FROM ADULTS IN SAINT PETERSBURG
606-607
EXPRESS METHOD OF GROWING BACTERIA ON THE MEMBRANE OF ANODIC ALUMINIUM OXIDE
607
THE DRUG RESISTANCE MUTATIONS OF THE HEPATITIS B VIRUS AMONG HIV-INFECTED INDIVIDUALS
607
INCREASE OF SELECTIVE AND GROWTH PROPERTIES OF A NUTRIENT MEDIUM FOR IDENTIFICATION AND ACCUMULATION TRICHOMONAS VAGINALIS
607-608
ANALYSIS OF THE PHAGE SENSITIVITY OF MICROORGANISMS OF A MICROBIOTA OF A VAGINA
608
S. AUREUS/C. ALBICANS MONO- AND DUAL-SPECIES BIOFILMS
608-609
MICROBIOLOGICAL MONITORING OF THE RESISTANCE OF HOSPITAL BACTERIAL FLORA WITHIN THE SYSTEM OF PREVENTION OF HEALTHCARE-ASSOCIATED INFECTIONS
609
GENETIC VARIANTS OF RESISTANCE DETERMINANT TO SILVER IN EPIDEMIC STRAINS OF ACINETOBACTER BAUMANNII
609
COMMENSAL STRAINS OF ESCHERICHIA COLI AND BETA-LACTAM RESISTANCE
609-610
VIRULENCE GENES AND PHYLOGENETIC GROUPS OF COMMENSAL STRAINS OF ESCHERICHIA COLI
610
THE SEROPREVALENCE H. PYLORI INFECTION IN DIFFERENT GEOGRAPHICAL REGIONS
610
INFLUENCE OF CHOLESTEROL ON THE GROWTH OF STAPHYLOCOCCUS spp.
610-611
SENSITIVITY OF BIOFILM CULTURES KLEBSIELLA spp. TO СIPROFLOXACIN
611
THE CORRELATION BETWEEN BIOFILM-FORMATION ABILITY OF KLEBSIELLA spp. AUTOSTRAINS AND ANTIBIOTIC SENSITIVITY OF PLANCTONIC CELLS
611
FERTILIZATION FAILURE IN HEIFERS INFECTED BY UREAPLASMA DIVERSUM
612
ANTIBIOTIC-RESISTANT KLEBSIELLA PNEUMONIAE IN THE GUT MICROBIOTA OF HEALTHY INDIVIDUALS
612
ANTIMICROBIAL RESISTANCE MECHANISMS IN BACTERIA STRAINS ISOLATED FROM FARM ANIMALS
612-613
DATA ANALYSIS OF MASS-SPECTRAL KLEBSIELLA PNEUMONIAE PROFILES TO PREDICT OF CARBAPENEM-RESISTANT STRAINS
613
NEW CHEMOTHERAPY FOR THE TREATMENT OF INFECTIOUS DISEASES
STUDY OF CYTOTOXIC AND ANTIPROLIFERATIVE ACTIVITY OF FUNGICIDAL SAPONIN TAUROSID Sx1 ON TRANSFORMED MAMMALIAN CELLS
614
ANTIMICROBIAL AND IMMUNOMODULATING ACTIVITY OF A TOPICAL GEL CONTAINING ACTIVE PEPTIDE COMPONENTS ON THE MODEL OF EXPERIMENTAL BACTERIAL VAGINITIS
614
ANTIMICROBIAL ACTIVITY OF SYNTHETIC ANALOGOUS OF CAPRINE PEPTIDES BACTENECINS TOWARDS DRUG-RESISTANT BACTERIA
614-615
ANTI-INFLAMMATORY EFFECT OF ITRACONAZOLE IN PATIENTS WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
615
SAPONIN TAUROSID Sx1 ADMINISTRATION ENHANCES ANTIBODY PRODUCTION IN MICE, CHALLENGED WITH INFLUENZA VIRUS OR IMMUNIZED WITH INFLUENZA GRIPPOL® VACCINE
615-616
ANTIBACTERIAL ACTIVITY OF SYNTHESIZED COMPOUNDS FROM DIFFERENT CLASSES OF CHEMICALS
616
DEVELOPMENT OF MAGNETICALLY CONTROLLED ANTIBACTERIAL COMPLEX EFFECTIVE AGAINST BIOFILMS
616
A STUDY OF THE POTENTIAL OF SPIDER SILK USE FOR THE DEVELOPMENT OF ANTIBACTERIAL DRUGS
617
CAPSULE SPECIFIC POLYSACCHARIDE DEPOLYMERASES OF KLEBSIELLA PNEUMONIAE BACTERIOPHAGES: IMPLICATION IN TYPING AND TREATMENT
617
DEVELOPMENT OF A NEW ANTI-INFLUENZA COMPOUND BASED ON CAMPHOR SCAFFOLD
617-618
COMBINED ANTIBACTERIAL ACTIVITY OF ANTIMICROBIAL PEPTIDES AND ANTISEPTIC AGENTS
618
EVALUATION OF THE EFFECTIVENESS OF PNEUMOCOCCAL VACCINES FOR PREVENTION OF COMMUNITY-ACQUIRED PNEUMONIA IN SERVICEMEN
618
INSTRUCTIONS TO AUTHORS
Instructions to Authors
619-621
EDITORIAL
Author index
622-624
Subject index
624

